Free Trial
NASDAQ:THAR

Tharimmune (THAR) Stock Price, News & Analysis

Tharimmune logo
$4.72 -0.25 (-5.03%)
Closing price 04:00 PM Eastern
Extended Trading
$4.84 +0.12 (+2.54%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tharimmune Stock (NASDAQ:THAR)

Key Stats

Today's Range
$4.31
$5.34
50-Day Range
$1.17
$4.97
52-Week Range
$0.95
$6.39
Volume
12.69 million shs
Average Volume
24.15 million shs
Market Capitalization
$21.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Strong Buy

Company Overview

Tharimmune Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

THAR MarketRank™: 

Tharimmune scored higher than 70% of companies evaluated by MarketBeat, and ranked 345th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tharimmune has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tharimmune has received no research coverage in the past 90 days.

  • Read more about Tharimmune's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Tharimmune has a P/B Ratio of 59.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.29% of the float of Tharimmune has been sold short.
  • Short Interest Ratio / Days to Cover

    Tharimmune has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tharimmune has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Tharimmune does not currently pay a dividend.

  • Dividend Growth

    Tharimmune does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.29% of the float of Tharimmune has been sold short.
  • Short Interest Ratio / Days to Cover

    Tharimmune has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tharimmune has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Tharimmune has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Tharimmune this week, compared to 0 articles on an average week.
  • Search Interest

    16 people have searched for THAR on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Tharimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tharimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $592,464.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.01% of the stock of Tharimmune is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.16% of the stock of Tharimmune is held by institutions.

  • Read more about Tharimmune's insider trading history.
Receive THAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter.

THAR Stock News Headlines

Why Is Tharimmune Stock (THAR) Blowing Up?
Elon Musk’s New Technology
Elon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.tc pixel
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 50.0%
Tharimmune CFO Don Kim Resigns
See More Headlines

THAR Stock Analysis - Frequently Asked Questions

Tharimmune's stock was trading at $2.03 at the start of the year. Since then, THAR shares have increased by 132.5% and is now trading at $4.72.

Tharimmune, Inc. (NASDAQ:THAR) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.06.

Tharimmune's stock reverse split before market open on Tuesday, May 28th 2024.The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Tharimmune's top institutional shareholders include Franklin Resources Inc. (1.07%) and XTX Topco Ltd (0.31%). Insiders that own company stock include Gravitas Capital Lp, Sireesh Appajosyula, Randy Milby and Sanam Parikh.
View institutional ownership trends
.

Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Blackboxstocks (BLBX).

Company Calendar

Last Earnings
8/14/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:THAR
Previous Symbol
NASDAQ:THAR
CIK
1861657
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$17.00
Potential Upside/Downside
+260.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.20 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,239.20%
Return on Assets
-365.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.17
Quick Ratio
0.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
59.00

Miscellaneous

Outstanding Shares
4,640,000
Free Float
4,171,000
Market Cap
$21.90 million
Optionable
Not Optionable
Beta
1.17
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:THAR) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners